Basel Medical Group Ltd
BMGL
$2.02
-$0.17-7.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -1.09% | 4.15% | |||
| Total Other Revenue | 0.00% | -62.12% | |||
| Total Revenue | -1.09% | 3.90% | |||
| Cost of Revenue | -1.09% | 21.47% | |||
| Gross Profit | -1.08% | -30.38% | |||
| SG&A Expenses | -1.10% | -82.36% | |||
| Depreciation & Amortization | -1.13% | 36.86% | |||
| Other Operating Expenses | -1.08% | 177.34% | |||
| Total Operating Expenses | -1.09% | 22.15% | |||
| Operating Income | 1.11% | -320.84% | |||
| Income Before Tax | 1.08% | -169.70% | |||
| Income Tax Expenses | 0.00% | 100.10% | |||
| Earnings from Continuing Operations | 1.08% | -143.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.08% | -143.60% | |||
| EBIT | 1.11% | -320.84% | |||
| EBITDA | 1.06% | -302.13% | |||
| EPS Basic | 1.35% | -143.53% | |||
| Normalized Basic EPS | 0.00% | -169.70% | |||
| EPS Diluted | 1.35% | -143.53% | |||
| Normalized Diluted EPS | 0.00% | -169.70% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||